Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
0.0915
-0.0273 (-22.98%)
At close: Feb 21, 2025, 4:00 PM
0.0919
+0.0004 (0.44%)
After-hours: Feb 21, 2025, 7:59 PM EST
Aditxt Revenue
Aditxt had revenue of $6.85K in the quarter ending September 30, 2024, a decrease of -94.49%. This brings the company's revenue in the last twelve months to $212.11K, down -71.70% year-over-year. In the year 2023, Aditxt had annual revenue of $645.18K, down -30.90%.
Revenue (ttm)
$212.11K
Revenue Growth
-71.70%
P/S Ratio
0.02
Revenue / Employee
$4,513
Employees
47
Market Cap
1.30M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ADTX News
- 1 day ago - Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025 - Business Wire
- 9 days ago - Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time - Business Wire
- 5 weeks ago - Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform - Business Wire
- 2 months ago - Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials - Business Wire
- 3 months ago - Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - PRNewsWire
- 3 months ago - Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares - Business Wire
- 3 months ago - Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders - Business Wire
- 3 months ago - Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem - Business Wire